3 Hyped Up Stocks We Keep Off Our Radar
Unpacking Q2 Earnings: Repligen (NASDAQ:RGEN) In The Context Of Other Drug Development Inputs & Services Stocks
2 Growth Stocks to Add to Your Roster and 1 We Avoid
Repligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q2 CY2026
Second quarter revenue of $204 million, a year-over-year increase of 12% as reported and 13% organic GAAP operating income increased 1% year-over-year while adjusted operating income increased 55% ...
Repligen (RGEN) Q2 Earnings: What To Expect
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of BioLife Solutions ...
Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know